Furthermore, the interaction between cancer cells, immune cells, mesenchymal stem cells (MSC), and CAFs led to the release of CXCL1, CXCL2/MIP (homologous to CXCL8/IL8 in humans) (from TNBrCa cells), CXCL16 (from CAFs), and C-C motif chemokine ligand 5 (CCL5) (from CAFs and MSCs), resulting in a more reactive stroma, inducing pro-tumoral actions, including chemotherapy resistance [56,57,58,59,60,61]. This evidence concerns the gene CXCL8 and cancer.